General Fusion founder to take part-time advisory role

The advisory term runs through December 31, 2027, with either party able to end the agreement on two months’ written notice.

Available on EDGAR 10/30/2026 - 07:30 AM EDT Accepted by SEC EDGAR 10/30/2026 - 07:30 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

General Fusion Group Ltd. (GFUZ) said Chief Science Officer and founder Dr. Michel Laberge entered into an employment agreement on October 27, 2026. Effective November 1, 2026, he will transition to the part-time advisory position of Founder Emeritus through December 31, 2027, unless the agreement ends earlier under its terms or is extended by agreement of both parties. Either party may terminate it on two months’ written notice. Dr. Laberge will be entitled to a base salary and participation in the Company’s cash bonus plan for calendar year 2026. The agreement also includes invention assignment, confidentiality, non-solicitation, non-competition and non-disparagement provisions.

Key Figures

Transition effective date: November 1, 2026 Scheduled term end date: December 31, 2027 Termination notice period: 2 months’ written notice +1 more

4 metrics

Transition effective date November 1, 2026 Effective date of the Founder Emeritus transition

Scheduled term end date December 31, 2027 Founder Emeritus agreement

Termination notice period 2 months’ written notice Either party may terminate the agreement

Cash bonus plan participation Calendar year 2026 Dr. Laberge’s participation under the agreement

Key Terms

invention assignment, non-solicitation, non-disparagement

3 terms

invention assignment regulatory

"customary invention assignment"

non-solicitation regulatory

"customary non-solicitation"

A non-solicitation clause is a contractual promise that one party will not actively try to lure away another party’s employees, customers, or suppliers. For investors, it signals protection of a company’s workforce and client base after a deal or partnership—reducing the risk that key staff or revenue sources will be poached and therefore helping preserve the business’s value, predictability, and post-transaction earnings. Think of it as an agreement not to knock on a neighbor’s door to take their business or team.

non-disparagement regulatory

"customary non-disparagement provisions"

A non-disparagement provision is a promise in an agreement that one party will not make negative public statements about the other, like a vow to avoid “badmouthing” a business or its leaders. Investors care because such promises protect reputation and can limit public criticism that might affect a company’s stock price, signal unresolved disputes, or introduce legal risk if enforcement leads to further costs or constrained disclosure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What role will Dr. Michel Laberge have at GFUZ after November 1, 2026?

He will transition to the part-time advisory position of Founder Emeritus effective November 1, 2026.

What compensation is included in Dr. Michel Laberge’s GFUZ agreement?

He will be entitled to receive a base salary and participate in the Company’s cash bonus plan for calendar year 2026.

How can Dr. Michel Laberge’s GFUZ agreement end early?

Either party may terminate the agreement on two months’ written notice. The agreement may also be extended if both parties agree.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16 Under the

Securities Exchange Act of 1934

For the month of October 2026

General Fusion Group Ltd.

(Name of registrant)

Not Applicable

(Translation of registrant’s name into English)

6020 Russ Baker Way

Richmond, BC V7B 1B4

Canada

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x  Form 40-F ¨

EXPLANATORY NOTE

On October 27, 2026, Dr. Michel Laberge, the Chief Science Officer and founder of General Fusion Group Ltd. (the “Company”), entered into an employment agreement with the Company (the “Employment Agreement”), pursuant to which, effective as of November 1, 2026, Dr. Laberge will transition to the part-time advisory position of Founder Emeritus until December 31, 2027, unless the Employment Agreement is terminated earlier in accordance with its terms, including upon two months’ written notice by either party or extended upon the agreement of both parties. As compensation for his service as Founder Emeritus, Dr. Laberge will be entitled to receive a base salary and, for calendar year 2026, to participate in the Company’s cash bonus plan. The Employment Agreement also includes customary invention assignment, confidentiality, non-solicitation, non-competition and non-disparagement provisions.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	General Fusion Group Ltd.
Date: October 30, 2026	By:	/s/ Robert Crystal
	Name:	Robert Crystal
	Title:	Senior Vice President, Finance